Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/bgzj2661 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Fred Saad und 10 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Patients with metastatic hormone-sensitive prostate cancer (mHSPC) were randomized 2:1 to darolutamide 600 mg twice daily + androgen-deprivation therapy (ADT) or placebo + ADT. Achievement of undetectable prostate-specific antigen (PSA) (
Zitieren
APA
Saad, F., Hanna, K. S., Haresh, K. P., Shor, N., Vjaters, E., Olmos, D., Littleton, N., Testa, I., Srinivasan, S., Verholen, F., & Briganti, A. (2026). Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/bgzj2661
Vancouver
Saad F, Hanna KS, Haresh KP, Shor N, Vjaters E, Olmos D, et al. Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/bgzj2661
BibTeX
@article{Saad2026,
author = {Saad, Fred and Hanna, Kirollos S. and Haresh, Kunhi Parambath and Shor, Neal and Vjaters, Egils and Olmos, David and Littleton, Natasha and Testa, Isabella and Srinivasan, Shankar and Verholen, Frank and Briganti, Alberto},
title = {Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/bgzj2661}
}
EUVIMED